Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates Company intends to shorten fully-enrolled Phase 3 dermatomyositis trial to 28 weeks from 52 weeks following recent developments in competitive landscape; data now expected as early as the second...